Clinical Efficacy Observation Of Diyushengbai Tablets Combining With RhG-CSF In Treating Bone Marrow Suppression Due To The Chemotherapy Of Taxane Drugs

Objective: Patients who had been regarded as severe bone marrow suppression(Ⅲ-Ⅳ) after using taxane drugs for chemotherapy were chosen to be studied in thisresearch. In this study, Diyushengbai tablets were used to prevent bone marrow andthen rhG-CSF (recombinant human granulocyte colony stimulating factor) werecombined to prevent and treat severe bone marrow suppression. The purpose is toprovide a scientific and reasonable method to prevent and cure bone marrowsuppression caused by taxane drugs, as well as provide clinical reference forcombination of first-line drug treatment for bone marrow suppression afterchemotherapy.Methods:278postoperative patients of malignant tumor who were severe bonemarrow suppression after taxane drugs chemotherapy were divided into research groupand control group,122of whom were chosen to be the research group, and all patientswere treated preventedly by Diyushengbai tablets in the whole process of chemotherapy.Then if they got severe bone marrow suppression,patients would be treated by thecombination Diyushengbai tablets with rhG-CSF; Another156patients were chosen tobe the control group, they were treated only by rhG-CSF, without Diyushengbai tablets.The observation time were divided into preventive medication period and combinationtreatment period. All patients were observed one chemotherapy cycle after combinationtreatment. In this study, the evaluation indicators were the peripheral blood, the averagedrug dosage and the average number of days, liver and kidney function and the controlof side effects of rhG-CSF. The purpose was to compare and analysis the recovery station of patients in two groups after treatment, and to evaluate the treatment effect andsafety of prevention and combination of treatment.Result:1.The analysis of bone marrow suppression in preventive medicationperiod: The occurring time of severe bone marrow suppression were compared, and thedifference was statistically significant (P<0.05). Compared with the control group, theoccurring time of severe bone marrow suppression in research group was later.2. The recovery situation of peripheral blood cells in combination treatment period:1) Counts of White blood cell and Neutrophils counts: On the4.5thday afterchemotherapy, compared with control group, the incidence of inhibition degree of WBCand NE (White blood cell and Neutrophils) in research group was obviously lower, andthe counts of WBC and NE were obviously higher. The difference was statisticallysignificant (P <0.05). On the8.5thday after chemotherapy, both of the counts of WBCand NE increased. Compared with control group, the research group increasedobviously, and the level of counts increased obviously. The difference was statisticallysignificant (P <0.05). On the20thday after chemotherapy and on the4.5thday after oncemore chemotherapy, the counts of WBC and NE in two groups both declined, but theresearch group fell more slowly, and the counts were significantly higher than thecontrol group. The difference was statistically significant (P <0.05).2) The comparisons of Platelet counts: On the4.5thday after chemotherapy,compared with control group, the incidence of inhibition degree of PLT in researchgroup was lower, and the counts of PLT were higher. The difference was statisticallysignificant (P <0.05). On the8.5thday after chemotherapy, the counts of PLT in bothgroups increased, but the research group had been increased more then control group,and the counts of PLT was higher. The difference was statistically significant (P <0.05).On the20thday after chemotherapy and4.5thday after once more chemotherapy, thecounts of PLT in two groups both declined, but the research group fell more slowly, andthe counts were higher than the control group. The difference was statisticallysignificant (P <0.05).3) The comparisons of Hemoglobin content: The difference of incidence ofinhibition degree and the content of the HB between the two groups was not statisticallysignificant (P>0.05) on the4.5thday、8.5thday、20thday after chemotherapy and4.5thday after once more chemotherapy. 2. The safety analysis of treatment: After treatment, according to the comparationof the function of the liver and kidney in two groups, there was no statisticallysignificant difference (P>0.05). The KPS score, adverse reaction fever, pains ofmuscle and bone and local response rate were compared, and the difference wasstatistically significant (P <0.05). The adverse reactions in research group weresignificantly lower than the control group.3. The doses discusion of treatment: It was compared that the average drug dosageand average number of days in two groups, the difference was statistically significant (P<0.05). Both the average dosage and days of rhG-CSF in the research group were lessthan the control group.Conclusion: It’s scientific and reasonable that the combination of Diyushengbaitablets with RhG-CSF can be complement each other on the treatment of bone marrowsuppression. It mainly reflects in:(1) The effect is obvious that the preventive use of Diyushengbai tablets and thecombination of rhG-CSF on preventing and treating to severe WBC, NE inhibitorycaused by taxane drugs chemotherapy, and the effect which recover the PLT declinecaused by chemotherapy is limited. Both have a synergy effect in combination with.(2) RhG-CSF can make up the shortcomings of Diyushengbai tablets slowlyelevating WBC. Meanwhile the Diyushengbai tablets can obviously reduce the rhG-CSF adverse effects.(3) From the perspective of drug consumption, that Diyushengbai tablets are usedto prevent bone marrow suppression before chemotherapy can reduce the averagedosage and days of rhG-CSF in combination treatment period.